Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 205Carcinoma, Non-Small-Cell Lung 130Neoplasms 101Neoplasm Metastasis 70Breast Neoplasms 66Ovarian Neoplasms 42Urinary Bladder Neoplasms 37Lung Neoplasms 37Triple Negative Breast Neoplasms 34Colorectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Cholangiocarcinoma 28Biliary Tract Neoplasms 27Carcinoma, Transitional Cell 23Lymphoma, Non-Hodgkin 22Adenocarcinoma 22Recurrence 21Lymphoma 20Fallopian Tube Neoplasms 18Stomach Neoplasms 15Sarcoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 15Non-Muscle Invasive Bladder Neoplasms 13Carcinoma, Pancreatic Ductal 13Nasopharyngeal Carcinoma 12Gallbladder Neoplasms 12Bile Duct Neoplasms 11Melanoma 10Carcinoma 10Solid Tumors 9

Interventions

Panitumumab 1PLX8394 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Histiocytosis × Gemcitabine × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡